{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T03:44:17Z","timestamp":1759117457347,"version":"3.41.2"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Misunderstanding temporal coincidence of adverse events during mass vaccination and invalid assessment of possible safety concerns have negative effects on immunization programs, leading to low immunization coverage. We conducted this systematic review and meta-analysis to identify the incidence rates of GBS that are temporally associated with viral vaccine administration but might not be attributable to the vaccines. By literature search in Embase and PubMed, we included 48 publications and 2,110,441,600 participants. The pooled incidence rate of GBS was 3.09 per million persons (95% confidence interval [CI]: 2.67 to 3.51) within six weeks of vaccination, equally 2.47 per 100,000 person-year (95%CI: 2.14 to 2.81). Subgroup analyses illustrated that the pooled rates were 2.77 per million persons (95%CI: 2.47 to 3.07) for individuals who received the influenza vaccine and 2.44 per million persons (95%CI: 0.97 to 3.91) for human papillomavirus (HPV) vaccines, respectively. Our findings evidence the GBS-associated safety of virus vaccines. We present a reference for the evaluation of post-vaccination GBS rates in mass immunization campaigns, including the SARS-CoV-2 vaccine.<\/jats:p>","DOI":"10.3389\/fimmu.2022.782198","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T04:33:27Z","timestamp":1643862807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Population-Based Incidence of Guillain-Barr\u00e9 Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Fengge","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cancan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa086","article-title":"Guillain-Barr\u00e9 Syndrome Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Detection and Coronavirus Disease 2019 in a Child","volume":"9","author":"Khalifa","year":"2020","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"B2","unstructured":"Coronavirus (COVID-19) Dashboard2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e9846","DOI":"10.7759\/cureus.9846","article-title":"Frequency of Neurological Presentations of Coronavirus Disease in Patients Presenting to a Tertiary Care Hospital During the 2019 Coronavirus Disease Pandemic","volume":"12","author":"Iltaf","year":"2020","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14243","article-title":"Two Cases of COVID-19 Presenting With a Clinical Picture Resembling Chilblains: First Report From the Middle East","volume":"45","author":"Alramthan","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.12691\/ajmcr-9-3-16","article-title":"Guillain-Barr\u00e9 Syndrome in a COVID-19 Patient: A Case Report and Review of Management Strategies","volume":"9","author":"Mostel","year":"2021","journal-title":"Am J Med Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30773-8","article-title":"What Defines an Efficacious COVID-19 Vaccine? A Review of the Challenges Assessing the Clinical Efficacy of Vaccines Against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61877-8","article-title":"Importance of Background Rates of Disease in Assessment of Vaccine Safety During Mass Immunisation With Pandemic H1N1 Influenza Vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet (Lond Engl)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"Cd001261","DOI":"10.1002\/14651858.CD001261.pub4","article-title":"Vaccines for Preventing Typhoid Fever","volume":"5","author":"Milligan","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"117263","DOI":"10.1016\/j.jns.2020.117263","article-title":"Guillain Barr\u00e9 Syndrome and its Variants as a Manifestation of COVID-19: A Systemic Review of Case Report and Case Series","volume":"420","author":"Sriwastava","year":"2021","journal-title":"J Neurol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.amepre.2010.05.022","article-title":"Evaluation of Guillain-Barr\u00e9 Syndrome Among Recipients of Influenza Vaccine in 2000 and 2001","volume":"39","author":"Burwen","year":"2010","journal-title":"Am J Prev Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1693005","article-title":"Guillain-Barre Syndrome","volume":"39","author":"Malek","year":"2019","journal-title":"Semin Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12202","article-title":"Guillain-Barr\u00e9 Syndrome in France: A Nationwide Epidemiological Analysis Based on Hospital Discharge Data (2008-2013)","volume":"22","author":"Delannoy","year":"2017","journal-title":"J Peripher Nerv Syst JPNS"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre Syndrome Following Vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.04.007","article-title":"Human Papillomavirus Vaccine and Demyelinating Diseases-A Systematic Review and Meta-Analysis","volume":"132","author":"Mouchet","year":"2018","journal-title":"Pharmacol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0233499","DOI":"10.1371\/journal.pone.0233499","article-title":"Cost-Effectiveness Evaluations of the 9-Valent Human Papillomavirus (HPV) Vaccine: Evidence From a Systematic Review","volume":"15","author":"Mahumud","year":"2020","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1662363","article-title":"Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-Analysis","volume":"16","author":"Wang","year":"2020","journal-title":"Hum Vaccines Immunotherapeut"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13426","DOI":"10.7759\/cureus.13426","article-title":"Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08.010405","article-title":"Association of Obstructive Sleep Apnea With Hypertension: A Systematic Review and Meta-Analysis","volume":"8","author":"Hou","year":"2018","journal-title":"J Glob Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying Heterogeneity in a Meta-Analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6616(03)00046-9","article-title":"Influenza Vaccination and Guillain Barre Syndrome","volume":"107","author":"Geier","year":"2003","journal-title":"Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative Risk of Guillain-Barr\u00e9 Syndrome Among Vaccinated and Unvaccinated Populations During the 2009 H1N1 Influenza Pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA J Am Med Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006736","article-title":"Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e58827","DOI":"10.1371\/journal.pone.0058827","article-title":"Safety of Pandemic (H1N1) 2009 Monovalent Vaccines in Taiwan: A Self-Controlled Case Series Study","volume":"8","author":"Huang","year":"2013","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No Increased Risk of Guillain-Barr\u00e9 Syndrome After Human Papilloma Virus Vaccine: A Self-Controlled Case-Series Study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.08.045","article-title":"Surveillance for Guillain-Barr\u00e9 Syndrome After 2015\u20132016 and 2016\u20132017 Influenza Vaccination of Medicare Beneficiaries","volume":"37","author":"Arya","year":"2019","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive Surveillance of Adverse Events of an MF59-Adjuvanted H1N1v Vaccine During the Pandemic Mass Vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Hum Vaccines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of Association of Guillain-Barr\u00e9 Syndrome With Vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1159\/000438752","article-title":"A Multicentric Prospective Incidence Study of Guillain-Barre Syndrome in Italy. The ITANG Study","volume":"45","author":"Benedetti","year":"2015","journal-title":"Neuroepidemiology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1086\/368055","article-title":"Measles-Rubella Mass Immunization Campaign in Albania, November 2000","volume":"187","author":"Bino","year":"2003","journal-title":"J\u00a0Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.097","article-title":"U.S. Postlicensure Safety Surveillance for Adolescent and Adult Tetanus, Diphtheria and Acellular Pertussis Vaccines: 2005-2007","volume":"31","author":"Chang","year":"2013","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.129","article-title":"Serious Adverse Events Following Receipt of Trivalent Inactivated Influenza Vaccine in Korea, 2003-2010","volume":"29","author":"Choe","year":"2011","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 Syndrome Following H1N1 Influenza Vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA  J Am Med Assoc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/14760584.2018.1388168","article-title":"Absence of Association Between Guillain-Barr\u00e9 Syndrome Hospitalizations and HPV-Vaccine","volume":"17","author":"Deceuninck","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.014","article-title":"Relationship Between Occurrence of Guillain-Barre Syndrome and Mass Campaign of Measles and Rubella Immunization in Iranian 5-14 Years Old Children","volume":"26","author":"Esteghamati","year":"2008","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.007","article-title":"Guillain-Barr\u00e9 Syndrome Following Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine in Korea With an Emphasis on Brighton Collaboration Case Definition","volume":"29","author":"Choe","year":"2011","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.009","article-title":"Risk of Guillain-Barr\u00e9 Syndrome Following Quadrivalent Human Papillomavirus Vaccine in the Vaccine Safety Datalink","volume":"35","author":"Gee","year":"2017","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10654-015-0047-0","article-title":"Risk of Guillain-Barr\u00e9 Syndrome After Exposure to Pandemic Influenza A(H1N1)pdm09 Vaccination or Infection: A Norwegian Population-Based Cohort Study","volume":"31","author":"Ghaderi","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws195","article-title":"Risk of Confirmed Guillain-Barre Syndrome Following Receipt of Monovalent Inactivated Influenza A (H1N1) and Seasonal Influenza Vaccines in the Vaccine Safety Datalink Project, 2009-2010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e67185","DOI":"10.1371\/journal.pone.0067185","article-title":"Guillain-Barr\u00e9 Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011","volume":"8","author":"Greene","year":"2013","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.080","article-title":"Post-Licensure Surveillance of Quadrivalent Live Attenuated Influenza Vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014","volume":"33","author":"Haber","year":"2015","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.048","article-title":"Post-Licensure Surveillance of Quadrivalent Inactivated Influenza (IIV4) Vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.018","article-title":"Post-Licensure Surveillance of Trivalent Live Attenuated Influenza Vaccine in Adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013","volume":"32","author":"Haber","year":"2014","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.013","article-title":"The Reporting Completeness of a Passive Safety Surveillance System for Pandemic (H1N1) 2009 Vaccines: A Capture-Recapture Analysis","volume":"30","author":"Huang","year":"2012","journal-title":"Vaccine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198106253042601","article-title":"Guillain-Barr\u00e9 Syndrome and the 1978-1979 Influenza Vaccine","volume":"304","author":"Hurwitz","year":"1981","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.21.2720","article-title":"Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine","volume":"294","author":"Izurieta","year":"2005","journal-title":"J Am Med Assoc"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3575","article-title":"Absence of Associations Between Influenza Vaccines and Increased Risks of Seizures, Guillain-Barr\u00e9 Syndrome, Encephalitis, or Anaphylaxis in the 2012-2013 Season","volume":"23","author":"Kawai","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8030431","article-title":"Incidence of Guillain-Barr\u00e9 Syndrome Is Not Associated With Influenza Vaccination in the Elderly","volume":"8","author":"Lee","year":"2020","journal-title":"Vaccines"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008553","article-title":"Safety of Influenza A (H1N1) Vaccine in Postmarketing Surveillance in China","volume":"364","author":"Liang","year":"2011","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1590\/s1678-9946201961043","article-title":"Adverse Events Following Quadrivalent HPV Vaccination Reported in Sao Paulo State, Brazil, in the First Three Years After Introducing the Vaccine for Routine Immunization (March 2014 to December 2016)","volume":"61","author":"Mauro","year":"2019","journal-title":"Rev Do Inst Med Trop Sao Paulo"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2015.03.003","article-title":"Surveillance of Adverse Events Following Vaccination in the French Armed Forces, 2011-2012","volume":"129","author":"Mayet","year":"2015","journal-title":"Public Health"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.01.056","article-title":"Adverse Events Following Pandemic Influenza Vaccine Pandemrix\u00ae Reported in the French Military Forces-2009-2010","volume":"29","author":"Mayet","year":"2011","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.031","article-title":"Evaluating the Safety of Influenza Vaccine Using a Claims-Based Health System","volume":"31","author":"McCarthy","year":"2013","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human Papillomavirus Vaccination and Risk of Autoimmune Diseases: A Large Cohort Study of Over 2 Million Young Girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.084","article-title":"Surveillance of Adverse Events After the First Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture (Flucelvax\u00ae) Reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015","volume":"33","author":"Moro","year":"2015","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.007","article-title":"Monitoring the Safety of High-Dose, Trivalent Inactivated Influenza Vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2011 \u2013 2019","volume":"38","author":"Moro","year":"2020","journal-title":"Vaccine"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.130","article-title":"Vaccine Adverse Events Reported in Post-Marketing Study of the Kitasato Institute From 1994 to 2004","volume":"25","author":"Nakayama","year":"2007","journal-title":"Vaccine"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.111165","article-title":"Risk of Guillain-Barr\u00e9 Syndrome After Measles-Mumps-Rubella Vaccination","volume":"138","author":"Patja","year":"2001","journal-title":"J\u00a0Pediatr"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.039","article-title":"Adverse Events Following HPV Vaccination: 11 Years of Surveillance in Australia","volume":"38","author":"Phillips","year":"2020","journal-title":"Vaccine"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt051","article-title":"Chart-Confirmed Guillain-Barre Syndrome After 2009 H1N1 Influenza Vaccination Among the Medicare Population, 2009-2010","volume":"178","author":"Polakowski","year":"2013","journal-title":"Am J Epidemiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.10.070","article-title":"Events Supposedly Attributable to Vaccination or Immunization During Pandemic Influenza A (H1N1) Vaccination Campaigns in Latin America and the Caribbean","volume":"33","author":"Ropero-\u00c1lvarez","year":"2015","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115973","article-title":"Reassessment of the Association Between Guillain-Barr\u00e9 Syndrome and Receipt of Swine Influenza Vaccine in 1976-1977: Results of a Two-State Study. Expert Neurology Group","volume":"133","author":"Safranek","year":"1991","journal-title":"Am J Epidemiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.087","article-title":"Near Real-Time Surveillance for Guillain-Barr\u00e9 Syndrome After Influenza Vaccination Among the Medicare Population, 2010\/11 to 2013\/14","volume":"35","author":"Sandhu","year":"2017","journal-title":"Vaccine"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.020","article-title":"Guillain-Barr\u00e9 Syndrome After Gardasil Vaccination: Data From Vaccine Adverse Event Reporting System 2006-2009","volume":"29","author":"Souayah","year":"2011","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.11.022","article-title":"Analysis of Data From the CDC\/FDA Vaccine Adverse Event Reporting System (1990-2009) on Guillain-Barre Syndrome After Hepatitis Vaccination in the USA","volume":"19","author":"Souayah","year":"2012","journal-title":"J Clin Neurosci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000336113","article-title":"Guillain-Barr\u00e9 Syndrome After H1N1 Vaccination in the United States: A Report Using the CDC\/FDA Vaccine Adverse Event Reporting System (2009)","volume":"38","author":"Souayah","year":"2012","journal-title":"Neuroepidemiology"},{"key":"B69","article-title":"Causality Assessment of Serious Neurologic Adverse Events Following the bOPV National Vaccination Campaign in Israel","volume":"18","author":"Tasher","year":"2016","journal-title":"Israel Med Assoc J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse Events Following Influenza A (H1N1) 2009 Monovalent Vaccines Reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of Trivalent Inactivated Influenza Vaccines in Adults: Background for Pandemic Influenza Vaccine Safety Monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2011.10.007","article-title":"Events Temporarily Associated With Anti-Influenza A (H1N1) Vaccination in Mexico","volume":"42","author":"Vidal","year":"2011","journal-title":"Arch Med Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws196","article-title":"Guillain-Barre Syndrome During the 2009-2010 H1N1 Influenza Vaccination Campaign: Population-Based Surveillance Among 45 Million Americans","volume":"175","author":"Wise","year":"2012","journal-title":"Am J Epidemiol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws197","article-title":"Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010","volume":"175","author":"Yih","year":"2012","journal-title":"Am J Epidemiol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwp027","article-title":"Antiganglioside Antibodies and Their Pathophysiological Effects on Guillain-Barr\u00e9 Syndrome and Related Disorders\u2013a Review","volume":"19","author":"Kaida","year":"2009","journal-title":"Glycobiology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 Syndrome: Pathogenesis, Diagnosis, Treatment and Prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barr\u00e9 Syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.013","article-title":"Guillain-Barr\u00e9 Syndrome and Influenza Vaccines: A Meta-Analysis","volume":"33","author":"Mart\u00edn Arias","year":"2015","journal-title":"Vaccine"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199812173392501","article-title":"The Guillain-Barr\u00e9 Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"New Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr072","article-title":"Guillain-Barre Syndrome, Influenzalike Illnesses, and Influenza Vaccination During Seasons With and Without Circulating A\/H1N1 Viruses","volume":"174","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Am J Epidemiol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100009136","article-title":"Epidemiology of Guillain-Barr\u00e9 Syndrome in the Province of Quebec","volume":"35","author":"Deceuninck","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"B82","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.phrs.2014.10.005","article-title":"Is Narcolepsy a Classical Autoimmune Disease","volume":"92","author":"Arango","year":"2015","journal-title":"Pharmacol Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine Adjuvants Alum and MF59 Induce Rapid Recruitment of Neutrophils and Monocytes That Participate in Antigen Transport to Draining Lymph Nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.085","article-title":"The Adjuvant Component \u03b1-Tocopherol Triggers via Modulation of Nrf2 the Expression and Turnover of Hypocretin In Vitro and its Implication to the Development of Narcolepsy","volume":"32","author":"Masoudi","year":"2014","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.782198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T04:33:32Z","timestamp":1643862812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.782198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2022.782198"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.782198","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"article-number":"782198"}}